Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma
Abstract
:1. Photobiomodulation and Regenerative Medicine
2. Chronic Hepatitis B Infection
3. Antiviral Properties of Curcumin and Applications
4. Curcumin and the Preventive Role in Hepatocellular Carcinoma
5. Photodynamic Therapy with Blue Laser and Curcumin in Hepatic Viral Infections
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
Abbreviations
AN | Analog nucleotides |
cccDNA | Covalently closed circular DNA |
GHSS | Global Health Sector Strategy |
HCC | Hepatocellular carcinoma |
HCV | Hepatitis C virus |
HBV | Hepatitis B virus |
IFN | Interferon |
IVBLBI | Intravenous blue laser blood irradiation |
MCP-1 | Monocyte chemoattractant/chemotactic protein-1 |
PBM | Photobiomodulation |
PDT | Photodynamic therapy |
ROS | Reactive oxygen species |
WHO | World Health Organization |
References
- The, L. Stem cells, regenerative medicine, and Prometheus. Editorial. Lancet 2018, 391, 814. [Google Scholar] [CrossRef]
- Hamblin, M.R. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017, 4, 337–361. [Google Scholar] [CrossRef] [PubMed]
- Weber, M.H. Basics, Science and Clinical Applications of Laserneedle Acupuncture. Available online: https://www.isla-laser.org/wp-content/uploads/Prsentation-LA-1-Basics-and-External-Laser-Therapy.pdf (accessed on 29 July 2019).
- WHO. Global Hepatitis Report. 2017. Available online: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (accessed on 1 June 2019).
- Bartosch, B. Hepatitis B and C Viruses and Hepatocellular Carcinoma. Viruses. 2010, 2, 1504–1509. [Google Scholar] [CrossRef] [PubMed]
- Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001, 94, 153–156. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.S.; El-Serag, H.B. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr. Gastroenterol. Rep. 2019, 21, 17. [Google Scholar] [CrossRef]
- Castelli, G.; Pelosi, E.; Testa, U. Liver cancer: Molecular characterization, clonal evolution and cancer stem cells. Cancers 2017, 9, 127. [Google Scholar] [CrossRef] [Green Version]
- Dorobantu, M. “State of Innovation”: Interferon-Free Therapies Have the Potential to Eliminate Hepatitis C. Available online: https://raportuldegarda.ro/articol/state-of-innovation-terapiile-interferon-free-hepatita-c/ (accessed on 1 June 2019).
- Obretin, D. What Do We Need to Know about Hepatitis B Virus Infection? Available online: https://doc.ro/hepatita-c/ce-trebuie-sa-stim-despre-infectia-cu-virusul-hepatitei-b (accessed on 1 June 2019).
- Loomba, R.; Liang, T.J. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions. Gastroenterology 2017, 152, 1297–1309. [Google Scholar] [CrossRef] [Green Version]
- Huang, Q.; Zhou, B.; Cai, D.; Zong, Y.; Wu, Y.; Liu, S.; Guo, H.; Sun, J.; Hou, J.; Colonno, R. THU-216-Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough. J. Hepatol. 2019, 70, e258–e259. [Google Scholar] [CrossRef]
- Suk-Fong Lok, A. Hepatitis B treatment: What we know now and what remains to be researched. Hepatol. Commun. 2018, 3, 8–19. [Google Scholar] [CrossRef] [Green Version]
- Bruzell, E.M.; Morisbak, E.; Tonnesen, H.H. Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. Photochem. Photobiol. Sci. 2005, 4, 523–530. [Google Scholar] [CrossRef]
- Rechtman, M.M.; Har-Noy, O.; Bar-Yishay, I.; Fishman, S.; Adamovich, Y.; Shaul, Y.; Halpern, Z.; Shlomai, A. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. Febs. Lett. 2010, 584, 2485–2490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mirzaei, H.; Shakeri, A.; Rashidi, B.; Jalili, A.; Banikazemi, Z.; Sahebkar, A. Phytosomal curcumin: A Review of pharmacokinetic, experimental and clinical studies. Biomed. Pharmacother. 2017, 85, 102–112. [Google Scholar] [CrossRef] [PubMed]
- Weber, M.; Weber, R.; Junggebauer, M. Photodynamic low-level-laser therapy. Chapter 6. In Medical Low-Level Laser Therapy-Foundations and Clinical Applications-Research Book, 2nd ed.; ISLA-International Society for Medical Laser Applications: Beverungen, Germany, 2015; pp. 431–465. ISBN 978-3-00-050017-6. [Google Scholar]
- Wei, Z.Q.; Zhang, Y.H.; Ke, C.Z.; Chen, H.X.; Ren, P.; He, Y.L.; Hu, P.; Ma, D.Q.; Luo, J.; Meng, Z.J. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation. World J. Gastroenterol. 2017, 23, 6252–6260. [Google Scholar] [CrossRef] [PubMed]
- Teng, C.F.; Yu, C.H.; Chang, H.Y.; Hsieh, W.C.; Wu, T.H.; Lin, J.H.; Wu, H.C.; Jeng, L.B.; Su, I.J. Chemopreventive effect of phytosomal curcumin on hepatitis B virus-related hepatocellular carcinoma in a transgenic mouse model. Sci. Rep. 2019, 9, 10338. [Google Scholar] [CrossRef] [Green Version]
- Kunwar, A.; Barik, A.; Priyadarsini, K.I.; Pandey, R. Absorption and fluorescence studies of curcumin bound to liposome and living cells. Barc. Newsl. 2007, 285, 213. [Google Scholar]
- Lubart, R.; Lipovski, A.; Nitzan, Y.; Friedmann, H. A possible mechanism for the bactericidal effect of visible light. Laser Ther. 2011, 20, 17–22. [Google Scholar] [CrossRef] [Green Version]
- Habiboallah, G.; Mahdi, Z.; Mahbobeh, N.N.; Mina, Z.J.; Sina, F.; Majid, Z. Bactericidal effect of visible light in the presence of erythrosine on Porphyromonas gingivalis and Fusobacterium nucleatum compared with diode laser, an in vitro study. Laser Ther. 2014, 23, 263–271. [Google Scholar]
- Mahdi, Z.; Habiboallh, G.; Mahbobeh, N.N.; Mina, Z.J.; Majid, Z.; Nooshin, A. Lethal effect of blue light-activated hydrogen peroxide, curcumin and erythrosine as potential oral photosensitizers on the viability of porphyromonas gingivalis and fusobacterium nucleatum. Laser Ther. 2015, 24, 103–111. [Google Scholar] [CrossRef] [Green Version]
- Intravenous Laser Therapy. Available Laser Modules. Blue 405 and 447 nm. Available online: https://www.webermedical.com/index.php?id=27&lang=en (accessed on 4 August 2019).
- Tsen, K.T.; Tsen, S.W.D.; Chang, C.L.; Hung, C.F.; Wu, T.C.; Kiang, J.G. Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol. J. 2007, 4, 50. [Google Scholar] [CrossRef] [Green Version]
- Tsen, K.T.; Tsen, S.W.D.; Chang, C.L.; Hung, C.F.; Wu, T.C.; Kiang, J.G. Inactivation of viruses with a very low power visible femtosecond laser. J. Phys. Condens. Matter. 2007, 19, 2102–2109. [Google Scholar] [CrossRef]
- Tsen, K.T.; Tsen, S.W.D.; Fu, Q.; Lindsay, S.M.; Kibler, K.; Jacobs, B.; Wu, T.C.; Karanam, B.; Jagu, S.; Roden, R.B.; et al. Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J. Biomed. Opt. 2009, 14, 064042. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tsen, K.T.; Cope, S.; Vaiana, S.; Tsen, S.W.D.; Fu, Q.; Lindsay, S.M.; Li, Z.; Kiang, J.G. Studies of inactivation of encephalomyocarditis virus, M13 bacteriophage, and Salmonella typhimurium by using a visible femtosecond laser: Insight into the possible inactivation mechanisms. J. Biomed. Opt. 2011, 16, 078003. [Google Scholar] [CrossRef] [PubMed]
- Tsen, S.W.D.; Chapa, T.; Beatty, W.; Tsen, K.T.; Yu, D.; Achilefu, S. Inactivation of enveloped virus by laser-driven protein aggregation. J. Biomed. Opt. 2012, 17, 128002. [Google Scholar] [CrossRef] [PubMed]
- Tsen, S.W.D.; Kingsley, D.H.; Poweleit, C.; Achilefu, S.; Soroka, D.S.; Wu, T.C.; Tsen, K.T. Studies of inactivation mechanism of non-enveloped icosahedral viruses by a visible ultrashort pulsed laser. Virol. J. 2014, 11, 20. [Google Scholar] [CrossRef] [PubMed]
- Kingsley, D.; Kuis, R.; Perez, R.; Basaldua, I.; Burkins, P.; Marcano, A.; Johnson, A. Oxygen-dependent laser inactivation of murine norovirus using visible light lasers. Virol. J. 2018, 15, 117. [Google Scholar] [CrossRef]
- Chiran, D.A.; Litscher, G.; Weber, M.H.; Ailioaie, L.M.; Ailioaie, C.; Litscher, D. Intravenous laser blood irradiation increases efficacy of etanercept in selected subtypes of juvenile idiopathic arthritis: An innovative clinical research approach. Evid. Based Complement. Altern. Med. 2013. [Google Scholar] [CrossRef] [Green Version]
- Moskvin, S.V.; Kisselev, S.B. Laser Therapy for Joint and Muscle Pain; Triada: Sewickley, PA, USA, 2017; Volume 216, pp. 175–176. ISBN 978-5-94789-787-6. [Google Scholar]
- Moskvin, S.V.; Khadartsev, A.A. Basic Techniques of Low Level Laser Therapy; Triada: Sewickley, PA, USA, 2017; Volume 144, pp. 11–12. ISBN 978-5-94789-772-2. [Google Scholar]
- Zhu, H.; Kochevar, I.E.; Behlau, I.; Zhao, J.; Wang, F.; Wang, Y.; Sun, X.; Hamblin, M.R.; Dai, T. Antimicrobial blue light therapy for infectious keratitis: Ex vivo and in vivo studies. Investig. Ophthalmol. Vis. Sci. 2017, 58.1, 586–593. [Google Scholar] [CrossRef] [Green Version]
- Dai, T.; Gupta, A.; Murray, C.K.; Vrahas, M.S.; Tegos, G.P.; Hamblin, M.R. Blue light for infectious diseases: Propionibacterium acnes, helicobacter pylori, and beyond? Drug Resist. Updat. 2012, 15, 223–236. [Google Scholar] [CrossRef] [Green Version]
- El-Bacha, T.; Da Poian, A.T. Virus-induced changes in mitochondrial bioenergetics as potential targets for therapy. Int. J. Biochem. Cell Biol. 2013, 45, 41–46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Araújo, N.C.; Fontana, C.R.; Gerbi, M.E.M.; Bagnato, V.S. Overall-mouth disinfection by photodynamic therapy using curcumin. Photomed. Laser Surg. 2012, 30, 96–101. [Google Scholar] [CrossRef] [PubMed]
- Karimian, M.S.; Pirro, M.; Majeed, M.; Sahebkar, A. Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth Factor Rev. 2017, 33, 55–63. [Google Scholar] [CrossRef] [PubMed]
- Jagetia, G.C.; Aggarwal, B.B. “Spicing up” of the immune system by curcumin. J. Clin. Immunol. 2007, 27, 19–35. [Google Scholar] [CrossRef] [PubMed]
- Yang, C.; Zhu, K.; Yuan, X.; Zhang, X.; Qian, Y.; Cheng, T. Curcumin has immunomodulatory effects on RANKL-stimulated osteoclastogenesis in vitro and titanium nanoparticle-induced bone loss in vivo. J. Cell Mol. Med. 2020, 24, 1553–1567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, T.; Marakkath, B.; Ye, Y.; Khobahy, E.; Yan, M.; Hutcheson, J.; Zhu, J.; Zhou, X.; Mohan, C. Curcumin attenuates both acute and chronic immune nephritis. Int. J. Mol. Sci. 2020, 21, 1745. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tuyaerts, S.; Rombauts, K.; Everaert, T.; Van Nuffel, A.M.T.; Amant, F. A phase 2 study to assess the immunomodulatory capacity of a lecithin-based delivery system of curcumin in endometrial cancer. Front. Nutr. 2019, 5, 138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mollazadeh, H.; Cicero, A.F.G.; Blesso, C.N.; Pirro, M.; Majeed, M.; Sahebkar, A. Immune modulation by curcumin: The role of interleukin-10. Crit. Rev. Food Sci. Nutr. 2019, 59, 89–101. [Google Scholar] [CrossRef]
- Boroumand, N.; Samarghandian, S.; Hashemy, S.I. Immunomodulatory, anti-inflammatory, and antioxidant effects of curcumin. J. Herbmed Pharm. 2018, 7, 211–219. [Google Scholar] [CrossRef] [Green Version]
- Bai, X.; Oberley-Deegan, R.E.; Bai, A.; Ovrutsky, A.R.; Kinney, W.H.; Weaver, M.; Zhang, G.; Honda, J.R.; Chan, E.D. Curcumin enhances human macrophage control of mycobacterium tuberculosis infection. Respirology 2016, 21, 951–957. [Google Scholar] [CrossRef]
- Antiga, E.; Bonciolini, V.; Volpi, W.; Del Bianco, E.; Caproni, M. Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris. BioMed. Res. Int. 2015, 283634. [Google Scholar] [CrossRef] [PubMed]
- Castro, C.N.; Barcala Tabarrozzi, A.E.; Winnewisser, J.; Gimeno, M.L.; Noguerol, M.A.; Liberman, A.C.; Paz, D.A.; Dewey, R.A.; Perone, M.J. Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes: Curcumin ameliorates autoimmunity in NOD. Clin. Exp. Immunol. 2014, 177, 149–160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.; Cho, S.; Li, Y.; Bae, C.S.; Park, K.M.; Par, D.H. Anti-inflammatory effect of curcuma longa and allium hookeri co-treatment via NF-κB and COX-2 pathways. Sci. Rep. 2020, 10, 5718. [Google Scholar] [CrossRef] [PubMed]
- Li, C.L.; Zhou, W.; Ji, G.; Zhang, L. Natural products that target macrophages in treating non-alcoholic steatohepatitis. World J. Gastroenterol. 2020, 26, 2155–2165. [Google Scholar] [CrossRef]
- Almatroodi, S.A.; Alrumaihi, F.; Alsahli, M.A.; Alhommrani, M.F.; Khan, A.; Rahmani, A.H. Curcumin, an active constituent of turmeric spice: Implication in the prevention of lung injury induced by benzo(a) pyrene (BaP) in rats. Molecules 2020, 25, 724. [Google Scholar] [CrossRef] [Green Version]
- Vitali, D.; Bagri, P.; Wessels, J.M.; Arora, M.; Ganugula, R.; Parikh, A.; Mandur, T.; Felker, A.; Garg, S.; Kumar, M.N.V.R.; et al. Curcumin can decrease tissue inflammation and the severity of HSV-2 infection in the female reproductive mucosa. Int. J. Mol. Sci. 2020, 21, 337. [Google Scholar] [CrossRef] [Green Version]
- Ullah, M.A.; Johora, F.T.; Sarkar, B.; Araf, Y.; Rahman, M.H. Curcumin analogs as the inhibitors of TLR4 pathway in inflammation and their drug like potentialities: A computer-based study. J. Recept. Signal. Transduct. Res. 2020, 40, 324–338. [Google Scholar] [CrossRef]
- Shimizu, K.; Funamoto, M.; Sunagawa, Y.; Shimizu, S.; Katanasaka, Y.; Miyazaki, Y.; Wada, H.; Hasegawa, K.; Morimoto, T. Anti-inflammatory action of curcumin and its use in the treatment of lifestyle-related diseases. Eur. Cardiol. 2019, 14, 117–122. [Google Scholar] [CrossRef] [Green Version]
- Szebeni, G.J.; Nagy, L.I.; Berkó, A.; Hoffmann, A.; Fehér, L.Z.; Bagyánszki, M.; Kari, B.; Balog, J.A.; Hackler, L.; Kanizsai, I.; et al. The anti-inflammatory role of mannich curcuminoids; special focus on colitis. Molecules 2019, 24, 1546. [Google Scholar] [CrossRef] [Green Version]
- Wal, P.; Saraswat, N.; Pal, R.S.; Wal, A.; Chaubey, M. A detailed insight of the anti-inflammatory effects of curcumin with the assessment of parameters, sources of ros and associated mechanisms. Open Med. J. 2019, 6, 64–76. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.; Liu, T.; Wang, Q.; Liu, J. Anti-inflammatory effect of combined tetramethylpyrazine, resveratrol and curcumin in vivo. BMC Complement. Altern. Med. 2017, 17, 233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Panahi, Y.; Hosseini, M.S.; Khalili, N.; Naimi, E.; Simental-Mendía, L.E.; Majeed, M.; Sahebkar, A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. Biomed Pharm. 2016, 82, 578–582. [Google Scholar] [CrossRef] [PubMed]
- Paciello, F.; Rita Fetoni, A.; Mezzogori, D.; Rolesi, R.; Di Pino, A.; Paludetti, G.; Grassi, C.; Troiani, D. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci. Rep. 2020, 10, 1063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- AlBasher, G.; Abdel-Daim, M.M.; Almeer, R.; Ibrahim, K.A.; Hamza, R.Z.; Bungau, S.; Aleya, L. Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. Env. Sci. Pollut. Res. 2020, 27, 6505–6514. [Google Scholar] [CrossRef]
- Konak, S.; Şener, E.H. Antioxidant effects of curcumin on the blood tissue in rats. MAKU J. Health Sci. Inst. 2019, 7, 8–14. [Google Scholar] [CrossRef]
- Nawab, A.; Li, G.; Liu, W.; Lan, R.; Wu, J.; Zhao, Y.; Kang, K.; Kieser, B.; Sun, C.; Tang, S.; et al. Effect of dietary curcumin on the antioxidant status of laying hens under high- temperature condition. J. Therm. Biol. 2019, 86, 102449. [Google Scholar] [CrossRef]
- Nawab, A.; Li, G.; An, L.; Wu, J.; Chao, L.; Xiao, M.; Zhao, Y.; Birmani, M.W.; Ghani, M.W. Effect of curcumin supplementation on TLR4 mediated non-specific immune responses in liver of laying hens under high-temperature conditions. J. Biol. 2019, 84, 384–397. [Google Scholar] [CrossRef]
- Meshkibaf, M.H.; Maleknia, M.; Noroozi, S. Effect of curcumin on gene expression and protein level of methionine sulfoxide reductase A (MSRA), SOD, CAT and GPx in Freund’s adjuvant inflammation-induced male rats. J. Inflamm. Res. 2019, 12, 241–249. [Google Scholar] [CrossRef] [Green Version]
- Borra, S.K.; Mahendra, J.; Gurumurthy, P.; Jayamathi; Iqbal, S.S.; Mahendra, L. Effect of curcumin against oxidation of biomolecules by hydroxyl radicals. J. Clin. Diagn. Res. 2014, 8, CC1–CC5. [Google Scholar] [CrossRef]
- Jat, D.; Parihar, P.; Kothari, S.C.; Parihar, M.S. Curcumin reduces oxidative damage by increasing reduced glutathione and preventing membrane permeability transition in isolated brain mitochondria. Cell Mol. Biol. 2013, 59, OL1899–OL1905. [Google Scholar]
- Norooznezhad, F.; Rodriguez-Merchan, E.C.; Asadi, S.; Norooznezhad, A.H. Curcumin: Hopeful treatment of hemophilic arthropathy via inhibition of inflammation and angiogenesis. Expert Rev. Hematol. 2020, 13, 5–11. [Google Scholar] [CrossRef] [PubMed]
- Mohapatra, T.K.; Nayak, R.R.; Subudhi, B.B. Exploration of anti-inflammatory and hepatoprotective effect of curcumin on co-administration with acetylsalicylic acid. J. Pharm. Pharmacogn. Res. 2019, 7, 310–322. [Google Scholar]
- Hassan, F.U.; Rehman, M.S.; Khan, M.S.; Ali, M.A.; Javed, A.; Nawaz, A.; Yang, C. Curcumin as an alternative epigenetic modulator: Mechanism of action and potential effects. Front. Genet. 2019, 10, 514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rainey, N.E.; Moustapha, A.; Petit, P.X. Curcumin, a multifaceted hormetic agent, mediates an intricate crosstalk between mitochondrial turnover, autophagy, and apoptosis. Oxid. Med. Cell Longev. 2020. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.; Cao, X.; Hu, X.; Li, S.; Wang, J. The anti-apoptotic, antioxidant and anti-inflammatory effects of curcumin on acrylamide-induced neurotoxicity in rats. BMC Pharm. Toxicol. 2020, 21, 62. [Google Scholar] [CrossRef]
- Liu, H.; Mao, Y.; Xia, B.; Long, C.; Kuang, X.; Huang, H.; Ning, J.; Ma, X.; Zhang, H.; Wang, R.; et al. Curcumin Inhibits Proliferation and Epithelial-Mesenchymal Transition in Lens Epithelial Cells through Multiple Pathways. BioMed. Res. Int. 2020, 6061894. [Google Scholar] [CrossRef]
- Chen, L.; Zhan, C.Z.; Wang, T.; You, H.; Yao, R. Curcumin inhibits the proliferation, migration, invasion, and apoptosis of diffuse large B-cell lymphoma cell line by regulating MiR-21/VHL axis. Yonsei Med. J. 2020, 61, 20–29. [Google Scholar] [CrossRef]
- Ma, C.; Zhuang, Z.; Su, Q.; He, J.; Li, H. Curcumin has anti-proliferative and pro-apoptotic effects on tongue cancer in vitro: A study with bioinformatics analysis and in vitro experiments. Drug Des. Devel. Ther. 2020, 14, 509–518. [Google Scholar] [CrossRef] [Green Version]
- Muangnoi, C.; Ratnatilaka Na Bhuket, P.; Jithavech, P.; Supasena, W.; Paraoan, L.; Patumraj, S.; Rojsitthisak, P. Curcumin diethyl disuccinate, a prodrug of curcumin, enhances anti-proliferative effect of curcumin against HepG2 cells via apoptosis induction. Sci. Rep. 2019, 9, 11718. [Google Scholar] [CrossRef] [Green Version]
- World Cancer Report: Cancer Research for Cancer Prevention. In World Cancer Reports; License: CC BY-NC-ND 3.0 IGO; Wild, C.P.; Weiderpass, E.; Stewart, B.W. (Eds.) International Agency for Research on Cancer: Lyon, France, 2020; pp. 355–358. ISBN 13-978-92-832-0447-3. Available online: http://publications.iarc.fr/586 (accessed on 1 September 2020).
- World Health Organization. Hepatitis, B. Available online: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (accessed on 15 September 2020).
- Cicalese, L.; Talavera, F.; Geibel, J.; Cagir, B.; Axelrod, D.A.; van Leeuwen, D.J. Hepatocellular Carcinoma. Available online: https://emedicine.medscape.com/article/197319-overview (accessed on 10 August 2020).
- Colombo, M.; Lleo, A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepatic. Oncol. 2018, 5, HEP03. [Google Scholar] [CrossRef] [Green Version]
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, L.R.; Torre, A.L.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Fourati, S.; Pawlotsky, J.M. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Research 2016, 5, F1000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, D.H.; Kang, H.S.; Kim, K.H. Roles of hepatocyte nuclear factors in hepatitis B virus infection. World J. Gastroenterol. 2016, 22, 7017–7029. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.J. Global elimination of viral hepatitis and hepatocellular carcinoma: Opportunities and challenges. Gut 2018, 67, 595–598. [Google Scholar] [CrossRef] [PubMed]
- D’Agnano, I.; Berardi, A.C. Extracellular Vesicles, A possible theranostic platform strategy for hepatocellular carcinoma—An overview. Cancers 2020, 12, 261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Hara, G.A.; McNaughton, A.L.; Maponga, T.; Jooste, P.; Ocama, P.; Chilengi, R.; Mokaya, J.; Liyayi, M.I.; Wachira, T.; Gikungi, D.M.; et al. Hepatitis B virus infection as a neglected tropical disease. PLoS Negl. Trop. Dis. 2017, 11, e0005842. [Google Scholar] [CrossRef] [Green Version]
- Dimri, M.; Satyanarayana, A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers 2020, 12, 491. [Google Scholar] [CrossRef] [Green Version]
- Mantovani, N.; Cicero, M.; Santana, L.C.; Silveira, C.; do Carmo, E.P.; Abrão, P.R.; Diaz, R.S.; Caseiro, M.M.; Komninakis, S.V. Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil. Virol. J. 2013, 10, 320. [Google Scholar] [CrossRef] [Green Version]
- Pallier, C.; Castéra, L.; Soulier, A.; Hézode, C.; Nordmann, P.; Dhumeaux, D.; Pawlotsky, J.M. Dynamics of hepatitis B virus resistance to lamivudine. Virol. J. 2005, 80, 643–653. [Google Scholar] [CrossRef] [Green Version]
- Liaw, Y.F.; Leung, N.W.; Chang, T.T.; Guan, R.; Tai, D.I.; Ng, K.Y.; Chien, R.N.; Dent, J.; Roman, L.; Edmundson, S.; et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000, 119, 172–180. [Google Scholar] [CrossRef]
- Lai, C.L.; Dienstag, J.; Schiff, E.; Leung, N.W.Y.; Atkins, M.; Hunt, C.; Brown, N.; Woessner, M.; Boehme, R.; Condreay, L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003, 36, 687–696. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tipples, G.A.; Ma, M.M.; Fischer, K.P.; Bain, V.G.; Kneteman, N.M.; Tyrrell, D.L. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996, 24, 714–717. [Google Scholar] [CrossRef] [PubMed]
- Allen, M.I.; Deslauriers, M.; Andrews, W.C.; Tipples, G.A.; Walters, K.A.; Tyrrell, D.J.; Brown, N.; Condrea, L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27, 1670–1677. [Google Scholar] [CrossRef] [PubMed]
- Bozdayi, A.M.; Uzunalimoğlu, Ö.; Türkyilmaz, A.R.; Aslan, N.; Sezgin, O.; Sahin, T.; Bozdayi, G.; Çinar, K.; Pai, S.B.; Pai, R. YSDD: A novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J. Viral Hepat. 2003, 10, 256–265. [Google Scholar] [CrossRef]
- Niesters, H.G.; De Man, R.A.; Pas, S.D.; Fries, E.; Osterhaus, A.D.M.E. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J. Med. Microbiol. 2002, 51, 695–699. [Google Scholar] [CrossRef]
- León, P.; Pozo, F.; Echevarría, M.J. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain. Enferm. Infecc. Microbiol. Clin. 2004, 22, 133–137. [Google Scholar] [CrossRef]
- Li, W.; Guo, Y.; Zhang, C.; Wu, R.; Yang, A.Y.; Gaspar, J.; Kong, A.N.T. Dietary phytochemicals and cancer chemoprevention: A perspective on oxidative stress, inflammation, and epigenetics. Chem. Res. Toxicol. 2016, 29, 2071–2095. [Google Scholar] [CrossRef]
- Kotecha, R.; Takami, A.; Espinoza, J.L. Dietary phytochemicals and cancer chemoprevention: A review of the clinical evidence. Oncotarget 2016, 7, 52517–52529. [Google Scholar] [CrossRef] [Green Version]
- Wang, D.; Veena, M.S.; Stevenson, K.; Tang, C.; Ho, B.; Suh, J.D.; Duarte, V.D.; Faull, K.F.; Mehta, K.; Srivatsan, E.S.; et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin. Cancer Res. 2008, 14, 6228–6236. [Google Scholar] [CrossRef] [Green Version]
- Jobin, C.; Bradham, C.A.; Russo, M.P.; Juma, B.; Narula, A.S.; Brenner, D.A.; Sartor, R.B. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J. Immunol. 1999, 163, 3474–3483. [Google Scholar]
- Plummer, S.M.; Holloway, K.A.; Manson, M.M.; Munks, R.J.L.; Kaptein, A.; Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex. Oncogene 1999, 18, 6013–6020. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maiti, P.; Dunbar, G.L. Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases. Int. J. Mol. Sci. 2018, 19, 1637. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Biswas, S.K.; McClure, D.; Jimenez, L.A.; Megson, I.L.; Rahman, I. Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: Mechanism of free radical scavenging activity. Antioxid. Redox Signal 2005, 7, 32–41. [Google Scholar] [CrossRef] [PubMed]
- Moghadamtousi, S.Z.; Kadir, H.A.; Hassandarvish, P.; Tajik, H.; Abubakar, S.; Zandi, K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed. Res. Int. 2014, 186864. [Google Scholar] [CrossRef]
- Shah, C.P.; Kharkar, P.S. Inosine 5′-monophosphate dehydrogenase inhibitors as antimicrobial agents: Recent progress and future perspectives. Future Med. Chem. 2015, 7, 1415–1429. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.J.; Yoo, H.S.; Kim, C.J.; Park, C.S.; Choi, M.S.; Kim, M.; Choi, H.; Min, J.S.; Kim, Y.S.; Yoon, S.W.; et al. Antiviral effect of curcuma longa linn extract against hepatitis B virus replication. J. Ethnopharmacol. 2009, 124, 189–196. [Google Scholar] [CrossRef] [PubMed]
- Tan, A.; Yeh, S.H.; Liu, C.J.; Cheung, C.; Chen, P.J. Viral hepatocarcinogenesis: From infection to cancer. Liver Int. 2008, 28, 175–188. [Google Scholar] [CrossRef]
- Levrero, M.; Zucman-Rossi, J. Mechanisms of HBV-induced hepatocellular carcinoma. J. Hepatol. 2016, 64, S84–S101. [Google Scholar] [CrossRef]
- Geng, M.; Xin, X.; Bi, L.Q.; Zhou, L.T.; Liu, X.H. Molecular mechanism of hepatitis B virus X protein function in hepatocarcinogenesis. World J. Gastroenterol. 2015, 21, 10732–10738. [Google Scholar] [CrossRef]
- Teng, C.F.; Wu, H.C.; Shyu, W.C.; Jeng, L.B.; Su, I.J. Pre-S2 Mutant-induced mammalian target of rapamycin signal pathways as potential therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma. Cell Transpl. 2017, 26, 429–438. [Google Scholar] [CrossRef] [Green Version]
- Menon, V.P.; Sudheer, A.R. Antioxidant and anti-inflammatory properties of curcumin. Adv. Exp. Med. Biol. 2007, 595, 105–125. [Google Scholar] [PubMed]
- He, Y.; Yue, Y.; Zheng, X.; Zhang, K.; Chen, S.; Du, Z. Curcumin, inflammation, and chronic diseases: How are they linked? Molecules 2015, 20, 9183–9213. [Google Scholar] [CrossRef] [PubMed]
- Hong, J.; Bose, M.; Ju, J.; Ryu, J.H.; Chen, X.; Sang, S.; Lee, M.J.; Yang, C.S. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25, 1671–1679. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mazidi, M.; Karimi, E.; Meydani, M.; Ghayour-Mobarhan, M.; Ferns, G.A. Potential effects of curcumin on peroxisome proliferator-activated receptor-gamma in vitro and in vivo. World J. Methodol. 2016, 6, 112–117. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.H.; Song, J.; Park, K.W. The multifaceted factor peroxisome proliferator-activated receptor gamma (PPARgamma) in metabolism, immunity, and cancer. Arch. Pharm. Res. 2015, 38, 302–312. [Google Scholar] [CrossRef]
- Wang, L.H.; Yang, X.Y.; Zhang, X.; Farrar, W.L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007, 110, 4373–4384. [Google Scholar] [CrossRef]
- Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008, 65, 1631–1652. [Google Scholar] [CrossRef]
- Johnson, S.M.; Gulhati, P.; Arrieta, I.; Wang, X.; Uchida, T.; Gao, T.; Evers, B.M. Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 2009, 29, 3185–3190. [Google Scholar]
- Saxton, R.A.; Sabatini, D.M. mTOR signaling in growth, metabolism, and disease. Cell 2017, 168, 960–976. [Google Scholar] [CrossRef] [Green Version]
- Mohandas, K.M.; Desai, D.C. Epidemiology of digestive tract cancers in India. V. Large and small bowel. Indian J. Gastroenterol. 1999, 18, 118–121. [Google Scholar]
- Shao, S.; Duan, W.; Xu, Q.; Li, X.; Han, L.; Li, W.; Zhang, D.; Wang, Z.; Lei, J. Curcumin suppresses hepatic stellate cell-induced hepatocarcinoma angiogenesis and invasion through downregulating CTGF. Oxidative Med. Cell. Longev. 2019, 8148510. [Google Scholar] [CrossRef] [PubMed]
- Nasr, M.; Selima, E.; Hamed, O.; Kazem, A. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur. J. Pharm. 2014, 723, 267–275. [Google Scholar] [CrossRef]
- Nassal, M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 2015, 64, 1972–1984. [Google Scholar] [CrossRef] [Green Version]
- Taranta, A.; Tien, S.B.; Zacher, B.J.; Rogalska-Taranta, M.; Manns, M.P.; Bock, C.T.; Wursthorn, K. Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples. J. Clin. Virol. 2014, 60, 354–360. [Google Scholar] [CrossRef] [PubMed]
- You, C.R.; Lee, S.W.; Jang, J.W.; Yoon, S.K. Update on hepatitis B virus infection. World J. Gastroenterol. 2014, 20, 13293–13305. [Google Scholar] [CrossRef] [PubMed]
- Cradick, T.J.; Keck, K.; Bradshaw, S.; Jamieson, A.C.; McCaffrey, A.P. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 2010, 18, 947–954. [Google Scholar] [CrossRef]
- Chen, J.; Zhang, W.; Lin, J.; Wang, F.; Wu, M.; Chen, C.; Zheng, Y.; Peng, X.; Li, J.; Yuan, Z. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol. Ther. 2014, 22, 303–311. [Google Scholar] [CrossRef] [Green Version]
- Lin, S.R.; Yang, H.C.; Kuo, Y.T.; Liu, C.J.; Yang, T.Y.; Sung, K.C.; Lin, Y.Y.; Wang, H.Y.; Wang, C.C.; Shen, Y.C.; et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo. Mol. Ther. Nucleic Acids 2014, 3, e186. [Google Scholar] [CrossRef]
- Seeger, C.; Sohn, J.A. Targeting hepatitis B virus with CRISPR/Cas9. Mol. Ther. Nucleic Acids 2014, 3, e216. [Google Scholar] [CrossRef]
- Ramanan, V.; Shlomai, A.; Cox, D.B.; Schwartz, R.E.; Michailidis, E.; Bhatta, A.; Scott, D.A.; Zhang, F.; Rice, C.M.; Bhatia, S.N. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci. Rep. 2015, 5, 10833. [Google Scholar] [CrossRef] [Green Version]
- Zhu, X.; Li, Q.; Chang, R.; Yang, D.; Song, Z.; Guo, Q.; Huang, C. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. PLoS ONE 2014, 9, e91303. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balasubramanyam, K.; Varier, R.A.; Altaf, M.; Swaminathan, V.; Siddappa, N.B.; Ranga, U.; Kundu, T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279, 51163–51171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mughal, M.H. Turmeric polyphenols: A comprehensive review. Integr. Food Nutr. Metab. 2019, 6. [Google Scholar] [CrossRef] [Green Version]
- Weber, M.; Weber, R.; Junggebauer, M. Intravenous laser blood irradiation—Introduction of a new therapy. Chapter 5. In Medical Low-Level Laser Therapy-Foundations and Clinical Applications-Research Book, 2nd ed.; ISLA-International Society for Medical Laser Applications: Beverungen, Germany, 2015; pp. 279–297. ISBN 978-3-00-050017-6. [Google Scholar]
- Giordano, A.; Tommonaro, G. Curcumin and cancer. Nutrients 2019, 11, 2376. [Google Scholar] [CrossRef] [Green Version]
- Raab, O. Uber die wirkung fluoreszierender stoffe auf infusorien. Ztg. Biol. 1900, 39, 524–526. [Google Scholar]
- Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380–387. [Google Scholar] [CrossRef]
- All Nobel Prizes in Physiology or Medicine. The Nobel Prize in Physiology or Medicine. 1903. Available online: https://www.nobelprize.org/prizes/lists/all-nobel-laureates-in-physiology-or-medicine/ (accessed on 5 September 2020).
- Von Tappeiner, H.; Jodlbauer, A. Die Sensiblilisierende Wirkung Fluoreszierender Substanzer Gesammte Untersuchungen uber die Photodynamische Erscheinerung; F.C.W. Vogel: Leipzig, Gremay, 1907. [Google Scholar]
- Abrahamse, H.; Hamblin, M.R. New photosensitizers for photodynamic therapy. Biochem. J. 2016, 473, 347–364. [Google Scholar] [CrossRef] [Green Version]
- Remembering Thomas Dougherty, PhD-Developer of Modern Cancer Therapy and Father of Photodynamic Therapy. Available online: https://www.internationalphotodynamic.com/new-blog/2018/11/16/remembering-thomas-dougherty-phd-developer-of-modern-cancer-therapy-and-father-of-photodynamic-therapy (accessed on 5 September 2020).
- Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011, 61, 250–281. [Google Scholar] [CrossRef]
- Van Straten, D.; Mashayekhi, V.; De Bruijn, H.S.; Oliveira, S.; Robinson, D.J. Oncologic Photodynamic therapy: Basic principles, current clinical status and future directions. Cancers 2017, 9, 19. [Google Scholar] [CrossRef]
- Maeding, N.; Verwanger, T.; Krammer, B. Boosting tumor-specific immunity using PDT. Cancers 2016, 8, 91. [Google Scholar] [CrossRef] [Green Version]
- Sivasubramanian, M.; Chuang, Y.C.; Lo, L.-W. Evolution of nanoparticle-mediated photodynamic therapy: From superficial to deep-seated cancers. Molecules 2019, 24, 520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Getting Photodynamic Therapy. Available online: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation/photodynamic-therapy.html (accessed on 6 September 2020).
- Shafirstein, G.; Bellnier, D.; Oakley, E.; Hamilton, S.; Potasek, M.; Beeson, K.; Parilov, E. Interstitial photodynamic therapy—A focused review. Cancers 2017, 9, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Reddy, R.M.; Kakarala, M.; Wicha, M.S. Clinical Trial Design for testing the stem cell model for the prevention and treatment of cancer. Cancers 2011, 3, 2696–2708. [Google Scholar] [CrossRef] [PubMed]
- Wiehe, A.; O’Brien, J.M.; Senge, M.O. Trends and targets in antiviral phototherapy. Photochem. Photobiol. Sci. 2019, 18, 2565–2612. [Google Scholar] [CrossRef] [PubMed]
- Enwemeka, C.S.; Bumah, V.V.; Masson-Meyers, D.S. Light as a potential treatment for pandemic coronavirus infections: A perspective. J. Photochem. Photobiol. B 2020, 207, 111891. [Google Scholar] [CrossRef] [PubMed]
- Masson-Meyers, D.S.; Bumah, V.V.; Castel, C.; Castel, D.; Enwemeka, C.S. Pulsed 450 nm blue light significantly inactivates Propionibacterium acnes more than continuous wave blue light. J. Photochem. Photobiol. B 2020, 202, 111719. [Google Scholar] [CrossRef]
- Biener, G.; Masson-Meyers, D.S.; Bumah, V.V.; Hussey, G.; Stoneman, M.R.; Enwemeka, C.S.; Raicu, V. Blue/violet laser inactivates methicillin-resistant Staphylococcus aureus by altering its transmembrane potential. J. Photochem. Photobiol. B 2017, 170, 118–124. [Google Scholar] [CrossRef] [Green Version]
- Bumah, V.V.; Aboualizadeh, E.; Masson-Meyers, D.; Eells, J.; Enwemeka, C.S.; Hirschmugl, C. Resistance of B-DNA to blue light induced damage in methicillin resistant Staphylococcus aureus. J. Photochem. Photobiol. B 2017, 167, 150–157. [Google Scholar] [CrossRef]
- Pang, P.; Wang, N.; Wang, C.; Yao, Y.; Fu, X.; Yu, W.; Cai, R.; Yao, M. 460 nm visible light irradiation eradicates MRSA via inducing prophage activation. J. Photochem. Photobiol. B 2017, 166, 311–322. [Google Scholar]
- Muller-Breitkreutz, K.; Mohr, H.; Briviba, K.; Sies, H. Inactivation of viruses by chemically and photchemically generated singlet molecular oxygen. J. Photochem. Photobiol. B 1995, 30, 63–70. [Google Scholar] [CrossRef]
- Bachmann, B.; Knuver-Hopf, J.; Lambrecht, B.; Mohr, H. Target structures for HIV-1 inactivation by methylene blue and light. J. Med. Virol. 1995, 47, 172–178. [Google Scholar] [CrossRef]
- Wagner, S.J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus. Med. Rev. 2002, 16, 61–66. [Google Scholar] [CrossRef] [PubMed]
- Richardson, T.B.; Porter, C.D. Inactivation of murine leukaemia virus by exposure to visible light. Virology 2005, 341, 321–329. [Google Scholar] [CrossRef] [Green Version]
- Dairaku, I.; Han, Y.; Yanaka, N.; Kato, N. Inhibitory effect of curcumin on IMP dehydrogenase, the target for anticancer and antiviral chemotherapy agents. Biosci. Biotechnol. Biochem. 2010, 74, 185–187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shafabakhsh, R.; Pourhanifeh, M.H.; Mirzaei, H.R.; Sahebkar, A.; Asemi, Z.; Mirzaei, H. Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy. Pharm. Res. 2019, 147, 104353. [Google Scholar] [CrossRef] [PubMed]
- Bose, S.; Panda, A.K.; Mukherjee, S.; Sa, G. Curcumin and tumor immune-editing: Resurrecting the immune system. Cell Div. 2015, 10, 6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sadreddini, S.; Baradaran, B.; Aghebati-Maleki, A.; Sadreddini, S.; Shanehbandi, D.; Fotouhi, A.; Aghebati-Maleki, L. Immune checkpoint blockade opens a new way to cancer immunotherapy. J. Cell Physiol. 2019, 234, 8541–8549. [Google Scholar] [CrossRef]
- Hanson, H.L.; Donermeyer, D.L.; Ikeda, H.; White, J.M.; Shankaran, V.; Old, L.J.; Shiku, H.; Schreiber, R.D.; Allen, P.M. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000, 13, 265–276. [Google Scholar] [CrossRef] [Green Version]
- Kalams, S.A.; Walker, B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 1998, 188, 2199–2204. [Google Scholar] [CrossRef] [Green Version]
- Randazzo, W.; Aznar, R.; Sánchez, G. Curcumin-Mediated Photodynamic Inactivation of Norovirus Surrogates. Food Env. Virol. 2016, 8, 244–250. [Google Scholar] [CrossRef]
- Buzzá, H.H.; Fialho de Freitas, L.C.; Moriyama, L.T.; Teixeira Rosa, R.G.; Bagnato, V.S.; Kurachi, C. Vascular effects of photodynamic therapy with curcumin in a chorioallantoic membrane model. Int. J. Mol. Sci. 2019, 20, 1084. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Biological Effects | References | Molecular Targets/Pathogenic Pathways | Conclusions |
---|---|---|---|
Immunomodulator | Yang, et al. [41] | Reduces the receptor activator of nuclear factor-kappa-B ligand (RANKL) ▼ Akt/NF-κB/NFATc1 pathways ▼ | Curcumin ameliorated the RANKL-mediated differentiation, fusion and maturation of osteoclasts and had an immunomodulatory effect on macrophage polarization; the protective effect of curcumin on osteoclast genesis was mediated by attenuating the up-regulation of Akt and p65 phosphorylation and the activation of the downstream transcription factor NFATc1 (Nuclear Factor of Activated T-cells, cytoplasmic 1). |
Wu, et al. [42] | NF-κB, MAPK, Akt and pBAD pathways ▼ | Curcumin treatment reduced activation of the NF-κB, MAPK (mitogen-activated protein kinase), Akt and pBAD (systematically araBp, a promoter found in bacteria) pathways either systemically, or within the inflamed kidneys. These findings suggest that natural food supplements could become an alternative approach to ameliorating immune-mediated kidney diseases. | |
Tuyaerts, et al. [43] | COX-2 expression in B cells, NK and T cells. Myeloid -Derived Suppressor Cell (MDSC): CD15+ & CD33+ granulocytic, and CD33+ monocytic. Expression of HLA-DR/CD45+ leukocytes | It is observed a downregulation of MHC expression by leukocytes, a reduction in the frequency of monocytes and a decreased inducible co-stimulator (ICOS) expression by CD8+ T cells upon Curcumin Phytosome (CP) intake, while the level of CD69 on CD16- NK cells was upregulated; did not find significant changes in inflammatory biomarker levels, frequencies of other immune cell types, T cell activation and COX-2 expression. | |
Mollazadeh, et al. [44] | Dendritic cells, macrophages, mast cells, natural killer cells, eosinophils, neutrophils, B cells, CD8+ T cells, TH1, TH2, TH17 & regulatory T cells | Curcumin is a natural anti-inflammatory compound able to induce the expression and production of IL-10 and enhancing its action on many tissues. | |
Boroumand, et al. [45] | Neutrophils, macrophages, monocytes, NK cells, dendritic cells (DCs), T and B cells Down regulating the expression of growth and survival promoting genes including c-Myc, BCL-XL and NF-κB ▼ | This review discusses current knowledge on the immunomodulatory, anti-inflammatory and antioxidant roles of curcumin, with the hope of recruiting curcumin as a therapeutic agent in the future therapeutic regimen. | |
Bai, et al. [46] | Inhibition of nuclear factor-kappa B (NF-κB) ▼ | Curcumin is a potent inducer of apoptosis—an effector mechanism used by macrophages to kill intracellular Mycobacterium tuberculosis (MTB). Curcumin enhanced the clearance of MTB in differentiated THP-1 human monocyte and in primary human alveolar macrophages. Curcumin was an inducer of caspase-3-dependent apoptosis and autophagy. | |
Antiga, et al. [47] | Th22 cells, a subpopulation of T cells ▼ | In conclusion, curcumin was demonstrated to be effective as an adjuvant therapy for the treatment of psoriasis vulgaris and to significantly reduce serum levels of IL-22. | |
Castro, et al. [48] | NF-kB, iNOS IL-6, TNF-alfa, IL-1 beta ▼ | Curcumin modulates the T lymphocyte response impairing proliferation and interferon (IFN)-γ production through modulation of T-box expressed in T cells (T-bet), a key transcription factor for proinflammatory T helper type 1 (Th1) lymphocyte differentiation, both at the transcriptional and translational levels. Reduces nuclear factor (NF)-κB activation in T cell receptor (TCR)-stimulated NOD lymphocytes and secretion of proinflammatory cytokines and nitric oxide (NO). | |
Anti-inflammatory | Lee, et al. [49] | IFN-γ, TNF alfa, IL1 beta, 6, 10, 13. 17 ▼ NF-κB/COX-2 pathway and iNOS ▼ | Authors conclude that C. longa and A. hookeri co-treatment synergistically inhibit inflammation by regulating the NF-κB/COX-2/iNOS pathway. |
Li, et al. [50] | Macrophage (M); Lipopolysaccharide (LPS), IFN-γ promote M1-type macrophage; IL-4, 10 and IL-13 promote M2-type macrophage polarization | Macrophages play a pivotal role in non-alcoholic fatty liver disease (NASH) development. Evidence for natural products or their active ingredients in the modulation of macrophage activation, recruitment, and polarization, as well as the metabolic status of macrophages were assessed. | |
Almatroodi, et al. [51] | TNF-α, IL-6 ▼ p53 expression▼ Glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase (CAT) Total Antioxidant Capacity (TAC)%▲ | Co-administration of curcumin (50 mg/kg) with BaP (50 mg/kg) exhibited significant reduction in TNF-α and the IL-6 level; significantly decreased the number of TUNEL-positive cells. Curcumin plus BaP decreased the p53 protein expression as compared with the BaP group and intensity of positivity was low as compared to the BaP only treated group. In addition, curcumin administered to BaP induced rats confirmed the improvement in SOD, CAT and GPx, total antioxidant capacity, and oxidative stress biomarker; significantly decreased the accumulation of cells in the G2/M phase and reduced the apoptotic cell death level increased by BaP. | |
Vitali, et al. [52] | IL-6, TNF-α and MCP-1 transcription factor NF-κB ▼ | Results show that delivery of curcumin nanoparticles directly into the vaginal tract of mice infected with HSV-2 abrogated CpG-oligodeoxynucleotide (ODN) induced inflammatory vaginal pathology and diminished the production of pro-inflammatory cytokines IL-6, TNF-α and MCP-1 in vaginal and cervical tissues. | |
Ullah, et al. [53] | Cycloxygenase-2 (COX-2)▼ Inhibitory kappa B Kinase (IKK) and TANK binding kinase-1 (TBK-1) of Toll Like Receptor 4 (TLR4) pathway ▲ | A continuous computerized examination of 14 compounds comprising curcumin, its derivatives and analogues were investigated as inhibitors of signaling proteins: cyclooxygenase-2 (COX-2), Kappaβ kinase inhibitor (IKK) and TANK-1 binding kinase (TBK-1), and Toll Path Like Receptor 4 (TLR4) involved in inflammation. This study recommends 6-Gingerol, Yakuchinone A and Yakuchinone B as the best inhibitors of COX-2, IKK and TBK-1 respectively among the selected curcumin analogues, which could be considered as potential anti-inflammatory agents in the search for new medication against inflammation. | |
Shimizu, et al. [54] | NF-kappa B TNF-alpha, IL-1beta myeloid differentiation protein 2-Toll-like receptor 4 co-receptor pathways▼ activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ▲ | A number of studies have reported the efficacy of curcumin and the mechanisms by which its anti-inflammatory activity could treat various lifestyle-related conditions associated with chronic inflammation, including atherosclerosis, heart failure, obesity, diabetes and other related diseases, such as dementia. Most of these studies have involved animal experiments; however, there are several reports on the benefits of curcumin use in humans. | |
Szebeni, et al. [55] | human PBMCs (peripheral blood mononuclear cells) NF-kB; TNF-alfa, IL4, IL6 ▼ | The effects of treatment with curcumin analogues in the inflamed colon of rats demonstrated a significant reduction in total tissue myeloperoxidase (MPO) activity, like the biological agent infliximab. Mannich curcuminoids reported herein possess a powerful anti-inflammatory activity. | |
Wal, et al. [56] | NF-κB, TNF-α▼ COX-2, inducible nitric oxide synthase (INS) and lipoxygenase (COX). INOs, LOX ▼ | Curcumin has the potential for curing inflammatory diseases as it blocks the mechanism of reactive oxygen species generation via inhibiting oxidative stress. Curcumin has prominent effect on inflammatory mediators like cytokines as a result of which it blocks the oxidation process in mitochondria of the cell and reduces inflammation. | |
Chen, et al. [57] | TNF-α, IL-1β and IL-6 as pro-inflammatory cytokines▼ NF-κB p65 ▼ | After four weeks of administration of combined two natural products with curcumin resulted in a decrease in the inflammatory cell infiltration, less thickness of the synovium and less volumetric increase in the synovial space at collagen-induced rat model arthritis; the level of TNF-α, IL-1β and IL-6 was significantly decreased in serum. Curcumin combination was able to inhibit the expression of NF-κB p65 and TNF-α which were closely related to the inflammatory process. | |
Panahi, et al. [58] | TNF-a, IL-6, TGF-b and MCP-1▼ macrophages monocytes NF-κBp65▼ | Study suggests a significant decrease in serum concentrations of TNF-a, IL-6, TGF-b and chemoattractant protein-1 (MCP-1) cytokines following curcumin supplementation in subjects with metabolic syndrome. | |
Antioxidant | Paciello, et al. [59] | Nuclear factor (erythroid-derived 2)-like 2 ») or Nrf2/Heme oxygenase-1 (HO-1) pathway; ROS downregulating p53 phosphorylation ▼ NF-κB, STAT-3 ▼ | The authors used two different polyphenols in adjuvant chemotherapy in several malignancies to avoid the chemoresistance and ototoxicity of the drug cisplatin. Both polyphenols had an antioxidant and self-protective action by up-regulating the Nrf-2/HO-1 pathways and down-regulating p53 phosphorylation; but only curcumin has been able to influence the inflammatory pathways that counteract NF-κB activation. In human cancer cells, curcumin transforms the antioxidant effect into a pro-oxidant and anti-inflammatory one. Curcumin has permissive and chemosensitive properties by targeting chemoresistant factors of cisplatin phosphorylation of Nrf-2, NF-κB and STAT-3. Therefore, polyphenols, mainly curcumin, which target ROS modulated pathways can be a promising tool for the treatment of cancer. Due to their biphasic antioxidant activity in normal cells under stress and pro-oxidant in cancer cells, these polyphenols are likely to involve an interaction between key factors Nrf-2, NF-κB, STAT-3 and p53. |
AlBasher, et al. [60] | (MDA) malondialdehyde, {NO} nitric oxide ▼, {GSH} reduced glutathione, {GPx} glutathione peroxidase, {SOD} superoxide dismutase, {CAT} catalase) ▲ Nrf2 ARE antioxidant response elements | This study was undertaken to assess the effects of resveratrol (RSV) and curcumin (CUR) on oxidative damage induced by insecticide fipronil (FPN). Co-treatment with RSV and CUR, mainly in combination, markedly alleviated the toxic effects and oxidative damage induced by FPN. Thus, liver enzyme activities, renal injury biomarkers, and lipid profiles in the sera, as well as the MDA, NO, and GSH concentrations and GPx, SOD, and CAT activities (liver, kidney, and brain), were normalized. RSV and CUR repaired oxidative disorders through the Nrf2 heterodimer that bound to antioxidant response elements (AER) and regulated the expression of antioxidant enzyme genes such as GPx, SOD and CAT. | |
Konak, et al. [61] | SOD, CAT, GPx ▲ ROS, NO▼ total antioxidant capacity (TAC) total oxidant capacity (TOC)▲ | Study investigated the antioxidant effect of curcumin, a phytochemical, on the blood tissue of rats. When the TAC and TOC levels of curcumin-supplemented feeding group were examined, the level was higher than the control group (P <0.05). Results of the study show that curcumin strengthens the antioxidant defense system. | |
Nawab, et al. [62] | CAT, SOD, GSH-Px and T-AOC▼ | The effects of increasing concentrations of dietary curcumin on the antioxidant parameters of layers maintained under high-temperature conditions for nine weeks were evaluated. Laying hens in all curcumin treatment groups had slightly higher activities of CAT, SOD, GSH-Px, and T-AOC in the liver, heart, and lungs, compared with heat stressed control group. It was concluded that dietary curcumin given to laying hens under heat stress may enhance their antioxidant status and alleviate the detrimental effects of stressful environmental conditions. | |
Nawab, et al. [63] | IL-6, IL-1β, TNF-α, ▼ TLR4, NF-κB; PCNA (proliferating cell nuclear antigen) ▼ | This study aimed to investigate the effect of curcumin supplementation on TLR4 mediated non-specific immune response in liver of laying hens under high-temperature conditions and heat stress. Authors showed that in the curcumin group treatment had reduced inflammatory responses (IL-6, IL-1β, TNF-α) as compared to control group. Furthermore, PCNA, TLR4 and its downstream gene expression as well as protein expression (TLR4, NF-κB and PCNA) were significantly downregulated in heat stress curcumin supplemented group as compared to control. | |
Meshkibaf, et al. [64] | Methionine Sulfoxide Reductase A (MSRA) SOD, CAT, GPx ▲ | Effect of curcumin on arthritis induced by adjuvant in rats, considering changes in methionine sulfoxide reductase A (MSRA) expression and antioxidant enzymes levels were analyzed. Curcumin can be used against inflammation. The increasing level of MSRA can be due to the antioxidant effect of curcumin. The enzymatic level changes (MSRA, SOD, CAT and GPx) may interfere with the aging process and delay it. | |
Borra, et al. [65] | MDA: Malondialdehyde, PC: Protein carbonyls, GSH: Reduced glutathione TAC: Total Antioxidant Capacity ▲; ROS▼ | Curcumin has the ability to protect the biomolecules like proteins, lipids and DNA from hydroxyl radical oxidation. These results demonstrate that exposure to OH in serum and plasma is a good experimental model for studying ROS-induced toxicity and evaluating the protective effects of various agents in vitro. | |
Jat, et al. [66] | GSH▲ Lipid peroxidation (LPO)▼ Protein carbonyl▼; ROS▼ | This study shows the strong anti-oxidative effects of curcumin and mitochondrially targeted curcumin against the lipid peroxidation, protein carbonylation and mitochondrial permeability transition induced by tert-butylhydroperoxide. Both curcumin and mitochondrially targeted curcumin significantly enhanced endogenous reduced glutathione level in the mitochondria thus preserving mitochondrial defense system against oxidative stress. | |
Anti-angiogenic | Norooznezhad, et al. [67] | CD68+ and CD11b+ cells; IL-1, IL-6, TNF-α, VEGF ▲ hypoxia-inducible factor 1α (HIF-1α) ▲ | Curcumin has a strong antioxidant potential, can decrease oxidative stress and it is able to inhibit the mentioned inflammatory and angiogenic factors such as IL-1, IL-6, TNF-α, VEGF, MMPs, and HIF-1α. |
Mohapatra, et al. [68] | Glutathione (GSH) ▼ Malondialdehyde (MDA) ▼ Superoxide dismutase (SOD) ▲ | The combination of curcumin and ASA (acetylsalicylic acid) significantly reduced foot edema and the formation of carrageenan-induced granuloma. Concomitant use of curcumin with ASA decreased malondialdehyde levels, while relatively increased superoxide dismutase and reduced glutathione, while proving protection against (histologically) induced hepatotoxicity by ASA. | |
Pro-Apoptotic/Antiproli-ferative | Hassan, et al. [69] | p53 level caspase activation ▲ tyrosine-regulated kinases (DYRKs) ▼ 26S proteasome activity ▼ | Potent role of curcumin as epigenic modulator, influence on transcriptional factors, antioxidant effects, mediation of inflammatory cytokines and angiogenesis modulation was proved. Curcumin is a potent proteasome inhibitor that increases p53 level and induces apoptosis by mitochondrial caspase activation. Curcumin also disrupts 26S proteasome activity by inhibiting DYRK2 in different cancerous cells, resulting in the inhibition of cell proliferation. |
Rainey, et al. [70] | AMP-activated protein kinase NRF1 (Nuclear Respiratory Factor 1); Nuclear factor (erythroid-derived 2)- like 2, also known as NFE2L2, Mitochondrial transcription factor A (TFAM) TFEB (Transcription Factor EB) G2/M cell cycle Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) -related signaling pathway. Activator protein 1 (AP-1), Caspase-10 | Multiple in vitro and in vivo preclinical studies have shown that curcumin is effective against various types of cancer. These potent the effects are determined by the ability of curcumin to induce G2/M cell cycle arrest, induction of autophagy, activation of apoptosis, disruption of molecules signaling, inhibition of invasion and metastasis and increasing the effectiveness of current chemotherapeutics. Low levels of curcumin enhance mitochondrial biogenesis in cells and tissues, mainly through the induction of the PGC-1α-related signaling pathway. | |
Guo, et al. [71] | Telomerase reverse transcriptase (TERT) ▲; Malondialdehyde (MDA) ▼ glutathione (GSH); superoxide ▲; dismutase (SOD)▲; glutathione peroxidase (GSH-Px); TNF-α and IL-1β in the cerebral homogenates ▼ TERT mRNA expression level▲ | Study evaluates the possible anti-apoptotic, antioxidant and anti-inflammatory effects of curcumin on the neurotoxicity caused by Acrylamide (ACR) in rats. Curcumin increased TERT mRNA expression level, suggesting curcumin might exert anti-apoptotic activity in ACR-induced neurotoxicity partly through maintaining TERT-related anti-apoptotic function. Curcumin at the dose of 100 mg/kg significantly decreased the levels MDA and IL-1β and TNF-α; increased levels GSH and SOD. | |
Liu, et al. [72] | G2/M arrest via possible inhibition of cell cycle-related proteins including Cyclin-dependent kinase 1 (CDK1), cyclin B1, and “cell division cycle” (CDC25C). Extracellular signal-regulated kinase (ERK1/2) and Protein Kinase B (Akt) pathways. Transforming growth factor-β (TGF-β)/Smad pathway. Notch signaling pathway. | This study shows that curcumin could suppress the proliferation and epithelial-mesenchymal transition (EMT) in lens epithelial cells (LECs) and it might be a potential therapeutic protection against visual loss induced by posterior capsule opacification (PCO). | |
Chen, et al. [73] | ▼ miR-21 in SU-DHL-8 cells, regulating Von Hippel-Lindau (VHL) expression in diffuse large B-cell lymphoma (DLBCL) cell line. | Curcumin exerts its anti-cancer effects, partly by targeting special microRNAs, in human cancers. MiR-21 is a key oncomir in carcinogenesis of multiple human cancers. Curcumin exerted its anti-proliferation, anti-migration, anti-invasion, and pro-apoptosis functions, at least partly, by repressing miR-21 and regulating VHL expression in DLBCL cell line. Study proved a possible molecular mechanism of curcumin-mediated anti-cancer effect. | |
Ma, et al. [74] | Caspase 3 and BAX (protein Bcl-2–associated X) ▲ reducing the expression of Bcl-2 in (human tongue squamous cell carcinoma) CAL 27 cells ▼ | This study focused on the mechanism underlying the therapeutic effect of curcumin against tongue cancer (TC). The effects of curcumin at different concentrations on the proliferation, migration, apoptosis, and cell cycle for TC cells were verified in vitro. Study revealed the anti-proliferative and pro-apoptotic roles of curcumin in CAL 27 cells, probably due to its role in modulating oxygen production and metabolism. Curcumin might be explored as a promising therapeutic method to improve TC treatment. | |
Muangnoi, et al. [75] | Caspase-3 and -9 activities and expression ▲ Bax and Bcl-2 protein expression LC3-II protein level ▲ | The aims of the present study were to determine the anti-proliferative effects and mechanisms of curcumin diethyl disuccinate (CurDD), a succinate ester prodrug of Curcumin (Cur), in vitro, in comparison with Cur. These results indicated that the bioavailable fraction (BF) of CurDD had anti-proliferation effect on HepG2 cells by apoptosis induction in HepG2 cells at significantly higher levels than that of Cur. Incubation of HepG2 cells with the BF of Cur increased caspase-3 and -9 activities. These results indicated that treatment of HepG2 cells with the BF of CurDD increased and, respectively, decreased the expression of Bax and Bcl-2 proteins, to a higher extent than in the case of the BF of Cur. The BF of CurDD increased the level of LC3-II significantly higher than the BF of Cur. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ailioaie, L.M.; Litscher, G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. Int. J. Mol. Sci. 2020, 21, 7150. https://doi.org/10.3390/ijms21197150
Ailioaie LM, Litscher G. Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2020; 21(19):7150. https://doi.org/10.3390/ijms21197150
Chicago/Turabian StyleAilioaie, Laura Marinela, and Gerhard Litscher. 2020. "Curcumin and Photobiomodulation in Chronic Viral Hepatitis and Hepatocellular Carcinoma" International Journal of Molecular Sciences 21, no. 19: 7150. https://doi.org/10.3390/ijms21197150